Holen Sie sich die Stockscreener-App
127.11
1.66%
2.23
Schlusskurs vom Vortag:
$124.88
Offen:
$125.06
24-Stunden-Volumen:
283.70K
Relative Volume:
0.20
Marktkapitalisierung:
$12.29B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
43.09
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+2.24%
1M Leistung:
+4.90%
6M Leistung:
-6.28%
1J Leistung:
-2.99%
1-Tages-Spanne:
$124.86
$127.85
1-Wochen-Bereich:
$122.66
$127.85
52-Wochen-Spanne:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
127.18 | 12.29B | 2.41B | 305.80M | 492.20M | 2.95 |
|
RGC
Regencell Bioscience Holdings Ltd
|
60.59 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
156.85 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.47 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.95 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.20 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN
Neurocrine Biosciences’ SWOT analysis: biotech stock balances Ingrezza success with pipeline potential - Investing.com
Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com
Endometriosis Market on Track for Major Expansion by 2034, - openPR.com
Neurocrine Loses Suit Challenging Hormone Treatment Patent - Law360
Judge Tosses Neurocrine’s Suit Over Spruce Hormone-Drug Patent - Bloomberg Law News
Neurocrine Biosciences names new Chief Information Officer By Investing.com - Investing.com South Africa
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - The Malaysian Reserve
Neurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock News - GuruFocus
Neurocrine Biosciences Names Lewis Choi as Chief Information Officer - marketscreener.com
Endometriosis Pain Pipeline 2025: Mechanism of Action, Route - openPR.com
Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer - StreetInsider
Neurocrine Biosciences names new Chief Information Officer - Investing.com
Former Thermo Fisher AI Chief Joins Neurocrine to Lead Digital Transformation During Product Launch Phase - Stock Titan
Congenital Adrenal Hyperplasia Market Growth Projections - openPR.com
(NBIX) Technical Data - news.stocktradersdaily.com
Nxera earns $15 million as Neurocrine advances schizophrenia drug - The Pharma Letter
Neurocrine Biosciences Projects Strong Ingrezza Sales For 2025 - Finimize
Nxera Pharma to Receive US$15 Million from Neurocrine - GlobeNewswire
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewswire Inc.
Analyst Expectations For Neurocrine Biosciences's Future - Benzinga
Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says - marketscreener.com
RBC Capital Reiterates Outperform Rating for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus
Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data - Nasdaq
[Latest] USA Tardive Dyskinesia Treatment Market: New Drugs, - openPR.com
Neurocrine (NBIX) Reports Positive Results from INGREZZA Study on Tardive Dyskinesia | NBIX Stock News - GuruFocus
Groundbreaking INGREZZA Study Reveals Life-Changing Benefits for Tardive Dyskinesia Patients in Just 4 Weeks - Stock Titan
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Quantisnow
Huntington's Disease Society hosts Team Hope Walk in Tulsa Saturday - KTUL
Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus
Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - MSN
In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III - insights.citeline.com
Neurocrine Biosciences director sells shares worth $1.16 million By Investing.com - Investing.com India
Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com
Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus
Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - The Malaysian Reserve
Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - Yahoo Finance
Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus
Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com
Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK
Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia
How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com
Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq
Cetera Investment Advisers Purchases 2,593 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com
Tourette Syndrome Treatment Market Detailed Analysis - openPR.com
Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus
Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):